SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-000891
Filing Date
2021-01-05
Accepted
2021-01-05 16:01:41
Documents
14
Period of Report
2021-01-05
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm211589d1_8k.htm   iXBRL 8-K 24656
2 EXHIBIT 99.1 tm211589d1_ex99-1.htm EX-99.1 10883
3 GRAPHIC image_001.jpg GRAPHIC 211029
  Complete submission text file 0001104659-21-000891.txt   503960

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA mrkr-20210105.xsd EX-101.SCH 3190
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrkr-20210105_lab.xml EX-101.LAB 34592
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrkr-20210105_pre.xml EX-101.PRE 22713
7 EXTRACTED XBRL INSTANCE DOCUMENT tm211589d1_8k_htm.xml XML 3615
Mailing Address 3200 SOUTHWEST FREEWAY SUITE 2250 HOUSTON TX 77027
Business Address 3200 SOUTHWEST FREEWAY SUITE 2250 HOUSTON TX 77027 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

IRS No.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37939 | Film No.: 21505353
SIC: 2834 Pharmaceutical Preparations